[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia]
- PMID: 15027317
[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia]
Abstract
Imatinib mesylate is a new drug that can inhibit the tyrosine kinase activity of Bcr-Abl, the receptors for platelet-derived growth factor receptor(PDGF) and stem cell factor, or c-kit. Chronic myeloid leukemia (CML) is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22 that results in a shortened chromosome 22, termed the Philadelphia(Ph) chromosome. As a result of the translocation, a fusion gene called the Bcr-Abl gene is created from two normal cellular genes, encoding a chimeric Bcr-Abl protein with a deregulated tyrosine kinase activity. The expression of Bcr-Abl tyrosine kinase has been shown to be necessary and sufficient for the transformed phenotype of CML cells. Imatinib can block the kinase activity of Bcr-Abl, thus inhibiting the proliferation of Ph-positive progenitors, and has shown activity against all phases of CML, though responses are most substantial and durable in patients in the chronic phase. An international phase III study which compared the efficacy of imatinib with that of interferon alpha combined with low-dose cytarabine in newly diagnosed chronic-phase CML showed the rate of major cytogenetic response at 24 months was 90%, including 82% of complete cytogenetic response. These results indicated that imatinib was superior to interferon-containing treatment as a first-line therapy. More than 10,000 patients worldwide, including those in Japan, have been treated with imatinib in clinical trials, and a lot of information has been accumulated on the use of this drug. The aim of this article is to review the use of this drug and the practical management of patients with chronic myeloid leukemia.
Similar articles
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402. N Engl J Med. 2001. PMID: 11287973 Clinical Trial.
-
New tyrosine kinase inhibitors in chronic myeloid leukemia.Haematologica. 2005 Apr;90(4):534-41. Haematologica. 2005. PMID: 15820950
-
Specific targeted therapy of chronic myelogenous leukemia with imatinib.Pharmacol Rev. 2003 Sep;55(3):401-23. doi: 10.1124/pr.55.3.4. Epub 2003 Jul 17. Pharmacol Rev. 2003. PMID: 12869662 Review.
-
Important therapeutic targets in chronic myelogenous leukemia.Clin Cancer Res. 2007 Feb 15;13(4):1089-97. doi: 10.1158/1078-0432.CCR-06-2147. Clin Cancer Res. 2007. PMID: 17317816 Review.
-
[Imatinib therapy for patients with chronic myelogenous leukemia].Gan To Kagaku Ryoho. 2005 Mar;32(3):297-303. Gan To Kagaku Ryoho. 2005. PMID: 15791812 Review. Japanese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous